I Heard about it from a Friend: Assessing Interest in Buprenorphine Treatment

Abstract

Background

In the United States, opioid abuse and dependence continue to be a growing problem, whereas treatment for opioid abuse and dependence remains fairly static. Buprenorphine treatment for opioid dependence is safe and effective but underutilized. Prior research has demonstrated low awareness and use of buprenorphine among marginalized groups. This study investigates syringe exchange participants’ awareness of, exposure to, and interest in buprenorphine treatment.

Methods

Syringe exchange participants were recruited from a mobile unit performing outreach to 9 street-side sites in New York City. Computer-based interviews were conducted to determine (1) opioid users’ awareness of, exposure to, and interest in buprenorphine treatment; and (2) the association between awareness or exposure and interest in buprenorphine treatment. Logistic regression models were used to examine the associations between awareness of, direct exposure (i.e., having taken buprenorphine) or indirect exposure (i.e., knowing someone who had taken buprenorphine)S to, and interest in buprenorphine treatment.

Results

Of 158 opioid users, 70% were aware of, 32% had direct exposure to, and 31% had indirect exposure to buprenorphine; 12% had been prescribed buprenorphine. Of 138 opioid users who had never been prescribed buprenorphine, 57% were interested in buprenorphine treatment. In multivariate models, indirect exposure was associated with interest in buprenorphine treatment (adjusted odds ratio [AOR] = 2.65, 95% confidence interval [CI]: 1.22–5.77), but awareness and direct exposure were not.

Conclusions

Syringe exchange participants were mostly aware of buprenorphine and interested in treatment, but few had actually been prescribed buprenorphine. Because indirect exposure to buprenorphine was associated with interest in treatment, future interventions could capitalize on indirect exposure, such as through peer mentorship, to address underutilization of buprenorphine treatment.

Keywords

Buprenorphine drug dependence syringe exchange programs heroin

Get full access to this article

View all access options for this article.

References

Substance Abuse and Mental Health Service Administration. 2012. Results from the 2011 National Survey on Drug Use and Health: National Findings, Rockville, MD: Substance Abuse and Mental Health Service Administration. NSDUH Series H-44, HHS Publication No. (SMA) 12–4713

Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. 2012. Treatment Episode Data Set (TEDS): 2000–2010. State Admissions to Substance Abuse Treatment Services, Rockville, MD: ubstance Abuse and Mental Health Services Administration. DASIS Series: S-63, HHS Publication No. SMA-12–4729

Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. 2012. The DAWN Report: Highlights of the 2010 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits, Rockville, MD: Substance Abuse and Mental Health Services Administration.

Ling

, Jacobs

Hillhouse

. 2010. From research to the real world: buprenorphine in the decade of the Clinical Trials Network. J Subst Abuse Treat, 38(Suppl 1): S53–S60.

Arfken

C L

, Johanson

C E

, di Menza

and Schuster

C R

. 2010. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: national surveys of physicians. J Subst Abuse Treat, 39: 96–104.

Fiellin

D A

. 2007. The first three years of buprenorphine in the United States: experience to date and future directions. J Addict Med, 1: 62–67.

Roman

P M

, Abraham

A J

and Knudsen

H K

. 2011. Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation. Addict Behav, 36: 584–589.

Mattick

R P

, Kimber

, Breen

and Davoli

. 2008. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev, : CD002207

Madden

, Lea

, Bath

and Winstock

A R

. 2008. Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment. Drug Alcohol Rev, 27: 671–678.

10.

Awgu

, Magura

and Rosenblum

. 2010. Heroin-dependent inmates’ experiences with buprenorphine or methadone maintenance. J Psychoactive Drugs, 42: 339–346.

11.

Korthuis

P T

, Gregg

, Rogers

W E

, McCarty

, Nicolaidis

and Boverman

. 2010. Patients’ reasons for choosing office-based buprenorphine: preference for patient-centered care. J Addict Med, 4: 204–210.

12.

Mattick

R P

, Ali

, White

J M

, O'Brien

, Wolk

and Danz

. 2003. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction, 98: 441–452.

13.

Fudala

P J

, Bridge

T P

Herbert

. 2003. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med, 349: 949–958.

14.

Davis

W R

and Johnson

B D

. 2008. Prescription opioid use, misuse, and diversion among street drug users in New York City. Drug Alcohol Depend, 92: 267–276.

15.

Ducharme

L J

and Abraham

A J

. 2008. State policy influence on the early diffusion of buprenorphine in community treatment programs. Subst Abuse Treat Prev Policy, 3: 17

16.

Stein

B D

, Gordon

A J

, Sorbero

, Dick

A W

, Schuster

and Farmer

. 2012. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone. Drug Alcohol Depend, 123: 72–78.

17.

Kresina

T F

, Litwin

A H

, Marion

, Lubran

and Clark

H W

. 2009. United States Government oversight and regulation of medication assisted treatment for the treatment of opioid dependence. J Drug Policy Anal, 2

18.

Kissin

, McLeod

, Sonnefeld

and Stanton

. 2006. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis, 25: 91–103.

19.

Alford

D P

, LaBelle

C T

Richardson

J M

. 2007. Treating homeless opioid dependent patients with buprenorphine in an office-based setting. J Gen Intern Med, 22: 171–176.

20.

Stancliff

, Joseph

, Fong

, Furst

, Comer

S D

and Roux

. 2012. Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations. J Addict Dis, 31: 278–287.

21.

Heller

D I

, Paone

, Siegler

and Karpati

. 2009. The syringe gap: an assessment of sterile syringe need and acquisition among syringe exchange program participants in New York City. Harm Reduct J, 6: 1

22.

Jarlais

D C

, Braine

and Friedmann

. 2007. Unstable housing as a factor for increased injection risk behavior at US syringe exchange programs. AIDS Behav, 11(6 Suppl): 78–84.

23.

McLean

. 2012. Needle exchange and the geography of survival in the South Bronx. Int J Drug Policy, 23: 295–302.

24.

Kidorf

, Disney

, King

, Kolodner

, Beilenson

and Brooner

R K

. 2005. Challenges in motivating treatment enrollment in community syringe exchange participants. J Urban Health, 82: 456–467.

25.

McLellan

A T

, Kushner

Metzger

. 1992. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat, 9: 199–213.

26.

Prochaska

J O

. 1996. A stage paradigm for integrating clinical and public health approaches to smoking cessation. Addict Behav, 21: 721–732.

27.

Riley

E D

, Safaeian

, Strathdee

S A

, Brooner

R K

, Beilenson

and Vlahov

. 2002. Drug user treatment referrals and entry among participants of a needle exchange program. Subst Use Misuse, 37: 1869–1886.

28.

Monte

A A

, Mandell

, Wilford

B B

, Tennyson

and Boyer

E W

. 2009. Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence. J Addict Dis, 28: 226–231.

29.

Bazazi

A R

, Yokell

, Fu

J J

, Rich

J D

and Zaller

N D

. 2011. Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. J Addict Med, 5: 175–180.

30.

McCarty

, Fuller

B E

Arfken

. 2007. Direct care workers in the National Drug Abuse Treatment Clinical Trials Network: characteristics, opinions, and beliefs. Psychiatr Serv, 58: 181–190.

31.

Knudsen

H K

, Ducharme

L J

and Roman

P M

. 2006. Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors. J Subst Abuse Treat, 30: 363–373.

32.

Knudsen

H K

, Ducharme

L J

and Roman

P M

. 2007. The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters. Drug Alcohol Depend, 87: 164–174.

33.

Knudsen

H K

, Abraham

A J

, Johnson

J A

and Roman

P M

. 2009. Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat, 37: 307–312.

34.

Ducharme

L J

and Roman

P M

. 2009. Opioid treatment programs in the Clinical Trials Network: representativeness and buprenorphine adoption. J Subst Abuse Treat, 37: 90–94.

35.

Gunderson

E W

, Fiellin

D A

, Levin

F R

, Sullivan

L E

and Kleber

H D

. 2006. Evaluation of a combined online and in person training in the use of buprenorphine. Subst Abus, 27: 39–45.

36.

Gordon

A J

, Kavanagh

Krumm

. 2011. Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychol Addict Behav, 25: 215–224.

37.

Cunningham

C O

, Kunins

H V

, Roose

R J

, Elam

R T

and Sohler

N L

. 2007. Barriers to obtaining waivers to prescribe buprenorphine for opioid addiction treatment among HIV physicians. J Gen Intern Med, 22: 1325–1329.

38.

Davey

M A

, Latkin

C A

, Hua

, Tobin

K E

and Strathdee

. 2007. Individual and social network factors that predict entry to drug treatment. Am J Addict, 16: 38–45.

39.

Christakis

N A

and Fowler

J H

. 2008. The collective dynamics of smoking in a large social network. N Engl J Med, 358: 2249–2258.

40.

Tracy

, Burton

Miescher

. 2011. Mentorship for alcohol problems (MAP): a peer to peer modular intervention for outpatients. Alcohol Alcohol, 47: 42–47.

41.

Smith

J E

, Meyers

R J

and Miller

W R

. 2001. The community reinforcement approach to the treatment of substance use disorders. Am J Addict, 10(Suppl): 51–59.

42.

Miller

W R

, Meyers

R J

and Hiller-Sturmhofel

. 1999. The community-reinforcement approach. Alcohol Res Health, 23: 116–121.

43.

Tracy

, Burton

, Nich

and Rounsaville

. 2011. Utilizing peer mentorship to engage high recidivism substance-abusing patients in treatment. Am J Drug Alcohol Abuse, 37: 525–531.

44.

Wells

, Klap

, Koike

and Sherbourne

. 2001. Ethnic disparities in unmet need for alcoholism, drug abuse, and mental health care. Am J Psychiatry, 158: 2027–2032.

45.

Paulozzi

L J

, Budnitz

D S

and Xi

. 2006. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf, 15: 618–627.

46.

Cicero

T J

, Inciardi

J A

and Munoz

. 2005. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002–2004. J Pain., 6: 662–672.